Header Logo

Connection

Johnny Mahlangu to Female

Back to Details
This is a "connection" page, showing publications Johnny Mahlangu has written about Female.
Johnny Mahlangu
Connection Strength
1,016
Female
  1. Extension Study With rVIII-SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A. Haemophilia. 2025 Mar; 31(2):214-223.
    View in: PubMed
    Score: 0,093
  2. Immunoglobulin subtyping and quantification in direct antiglobulin test: positive haemolysis in an HIV-prevalent setting. J Clin Pathol. 2022 Feb; 75(2):117-120.
    View in: PubMed
    Score: 0,070
  3. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019 May; 25(3):382-391.
    View in: PubMed
    Score: 0,062
  4. Analytical Performance of a New Immunoturbidimetric Assay for von Willebrand Factor (VWF) Activity Testing. Clin Lab. 2019 Apr 01; 65(4).
    View in: PubMed
    Score: 0,062
  5. Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. J Clin Apher. 2019 Feb; 34(1):44-50.
    View in: PubMed
    Score: 0,061
  6. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia. 2018 Nov; 24(6):921-929.
    View in: PubMed
    Score: 0,060
  7. The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):224-229.
    View in: PubMed
    Score: 0,054
  8. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia. 2017 Jan; 23(1):33-41.
    View in: PubMed
    Score: 0,052
  9. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 2016 Nov; 22(6):873-879.
    View in: PubMed
    Score: 0,052
  10. Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia. J Genet Couns. 2015 Dec; 24(6):978-86.
    View in: PubMed
    Score: 0,047
  11. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. 2025 Jan; 31(1):78-86.
    View in: PubMed
    Score: 0,023
  12. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
    View in: PubMed
    Score: 0,020
  13. A cohort study of the relationship between anaemia, mean corpuscular volume and mortality among a CKD population in South Africa. Afr Health Sci. 2021 Dec; 21(4):1764-1775.
    View in: PubMed
    Score: 0,019
  14. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021 08; 19(8):1883-1887.
    View in: PubMed
    Score: 0,018
  15. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
    View in: PubMed
    Score: 0,018
  16. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021 01; 19 Suppl 1:32-41.
    View in: PubMed
    Score: 0,018
  17. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost. 2021 01; 19 Suppl 1:21-31.
    View in: PubMed
    Score: 0,018
  18. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018.
    View in: PubMed
    Score: 0,017
  19. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol. 2020 09 29; 21(1):415.
    View in: PubMed
    Score: 0,017
  20. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020 10; 67(10):e28474.
    View in: PubMed
    Score: 0,017
  21. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia. 2020 Nov; 26(6):e262-e271.
    View in: PubMed
    Score: 0,017
  22. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.
    View in: PubMed
    Score: 0,017
  23. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.
    View in: PubMed
    Score: 0,016
  24. Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa. PLoS One. 2018; 13(10):e0204899.
    View in: PubMed
    Score: 0,015
  25. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. Haemophilia. 2018 Nov; 24(6):911-920.
    View in: PubMed
    Score: 0,015
  26. Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. Haemophilia. 2017 11; 23(6):e536-e538.
    View in: PubMed
    Score: 0,014
  27. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017 May; 23(3):392-399.
    View in: PubMed
    Score: 0,013
  28. Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia. 2016 Nov; 22(6):912-918.
    View in: PubMed
    Score: 0,013
  29. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872.
    View in: PubMed
    Score: 0,013
  30. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa. Antiviral Res. 2016 Mar; 127:90-8.
    View in: PubMed
    Score: 0,012
  31. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016 Jan; 22(1):72-80.
    View in: PubMed
    Score: 0,012
  32. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77.
    View in: PubMed
    Score: 0,012
  33. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014 Sep; 20(5):687-92.
    View in: PubMed
    Score: 0,011
  34. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12; 369(24):2313-23.
    View in: PubMed
    Score: 0,011
  35. Local reference ranges for full blood count and CD4 lymphocyte count testing. S Afr Med J. 2009 Apr; 99(4):243-8.
    View in: PubMed
    Score: 0,008
  36. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol. 2008; 153(11):2049-58.
    View in: PubMed
    Score: 0,008
  37. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood. 2008 Jun 15; 111(12):5592-600.
    View in: PubMed
    Score: 0,007
  38. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and multiple myeloma in South Africa. Diagn Mol Pathol. 2001 Jun; 10(2):95-9.
    View in: PubMed
    Score: 0,005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.